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Structure of the ergothioneine-biosynthetic amidohydrolase EgtC 
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Abstract: The ubiquitous sulfur metabolite ergothioneine is 
biosynthesized by oxidative attachment of a sulfur atom to the 
imidazole ring of N-trimethylhistidine. Most actinobacteria, 
including Mycobacterium tuberculosis, use -glutamyl cysteine as 
a sulfur donor. In subsequent steps the carbon scaffold of -
glutamyl cysteine is removed by the glutamine amidohydrolase 
EgtC and the -lyase EgtE. We solved the crystal structure of 
EgtC from M. smegmatis in complex with its physiological 
substrate. The active site of EgtC is surprisingly conserved even 
in homologs that are clearly not involved in ergothioneine 
production. The phylogenetic distribution of EgtC-like enzymes 
indicate that their last common ancestor may have emerged for a 
different purpose than ergothioneine production.  
Introduction 
Ergothioneine (1, Figure 1) is a sulfur containing histidine 
derivative that occurs in plants, fungi, animal including 
humans and a broad range of bacteria. Because of its 2-
mercaptoimidazole side chain, ergothioneine has long been 
suspected to play a role in cellular redox homeostasis.[1] 
Several recent studies on the cytoprotective effects of 
ergothioneine on human cells,[2], in zebrafish[3] in lower 
eukaryotes[4] and in bacteria[5] provide growing support for 
this idea.[6] Furthermore, the latest discovery that 
ergothioneine also serves as a cofactor in bacterial 
secondary metabolite biosynthesis[7] indicates that this 
molecule may be even more versatile. 
As a prerequisite to discover such functions, we started to 
characterize the ergothioneine biosynthetic machinery in 
Mycobacteria.[8] Almost all sequenced actinobacteria, 
including the pathogen Mycobacterium tuberculosis or the 
saprophyte Mycobacterium smegmatis, contain a five-gene 
cluster (egtABCDE) which enables the cells to produce 
ergothioneine from the primary metabolites cysteine, 
glutamate, histidine and S-adenosylmethionine (SAM, Figure 
1). [8a] The -glutamyl cysteine (GC) synthase EgtA[9] and the 
SAM-dependent histidine methyltransferase EgtD[8b] provide 
the substrates for EgtB-catalyzed production of the central 
intermediate -glutamyl cysteine sulfoxide trimethyl histidinyl 
conjugate (sulfoxide 3, Figure 1). This compound is substrate 
to the amidohydrolase EgtC, which cleaves the -glutamyl tail 
to produce sulfoxide 4 (Figure 1), which in turn is converted to 
ergothioneine by the pyridoxal 5-phosphate-dependent β-
lyase EgtE.[8a] This pathway is not universal. For example, 
Neurospora crassa and Schizosaccharomyces pombe use 
cysteine directly as sulfur donor to make sulfoxide 4 and 
consequently bypass the EgtC catalyzed step (gray, Figure 
1).[10] Given that the complete egtABCDE gene cluster[11] is an 
exclusive trait of actinobacterial genomes it may be even 
possible that the five step biosynthetic route is largely limited 
to this phylum. On the other hand, EgtC-like enzymes 
frequently occur in proteobacteria, cyanobacteria and fungi, 
including N. crassa. It is impossible to infer from primary 
sequence data alone whether these homologs are bona fide 
EgtCs or whether they serve unrelated functions.  
Sequence homology places EgtC in a large superfamily of 
Ntn-hydrolases (CL0052) named for their common use of an 
N-teminal serine, threonine or cysteine residue as catalytic
nucleophile.[12] This superfamily comprises the proteasome,[13]
penicillin amidase,[14] -glutamyl-transpeptidase[15] and many
amidohydrolases that remove glutamyl- or asparaginyl- 
residues from ammonia or more complex amines.[16] Despite
the common Ntn-hydrolase fold and similar catalytic activities,
members of this superfamily do not necessarily share
recognizable sequence homology.[16f] In keeping this family
tradition, EgtC shares almost no recognizable sequence
similarity with any other protein for which both structure and
function are known.
In this paper we report the crystal structure of mycobacterial 
EgtC in complex with either the substrate sulfoxide 3, or the 
product glutamate. These structures reveal a set of active site 
residues that determine the substrate specificity of EgtC. 
Sequence comparison with homologs from organisms that do 
not use EgtC in ergothioneine biosynthesis find these 
specificity determinants more conserved than the 
physiological function. Based on phylogenetic distribution and 
active site conservation we conclude that the last common 
ancestor of EgtC-like enzymes may have emerged for a 
different purpose than ergothioneine biosynthesis. In addition, 
the presented structures define the sulfoxide stereochemistry 
of sulfoxide 3. This information sheds new light onto the 
catalytic mechanism of the iron (II) dependent C-S bond 
forming sulfoxide synthase EgtB.  
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Figure 1. Mycobacterial ergothioneine biosynthesis is catalyzed by enyzmes EgtA-E.[8a] The glutamine amidohydrolase EgtC cleaves the γ-glutamyl moiety of the 
central intermediate sulfoxide 3. In gray: Cysteine serves as sulfur donor in the abbreviated ergothioneine biosynthetic pathway described for N. crassa.[10a, 10b]
Results and Discussion 
Overall structure. We crystallized EgtCwt in the apo form and 
in complex with glutamine/glutamate. The first structure was 
determined using selenomethionine labeled protein. To obtain 
a stable complex with the substrate sulfoxide 3 (termed 4NK 
in the PDB file) we constructed an EgtC variant in which the 
N-terminal cysteine nucleophile was mutated to alanine 
(EgtCC2A). The asymmetric unit of these crystals contained 
either twelve protein chains (EgtCwt apo, EgtCC2A_4NK) in 
space group P21 or four protein chains in space group 
P212121 (EgtCC2A_Gln). The crystal contacts between 
neighboring chains are conserved in both crystal forms. In 
space group P212121, the asymmetric unit is formed by an 
EgtC tetramer. Oligomer prediction by PISA,[17] and analytical 
size exclusion chromatography of purified EgtC indicated that 
this quaternary structure is also relevant for the protein in 
solution. 
 
The tertiary structure of EgtC consists of a typical Ntn-
hydrolase fold characterized by a four-layer  +  structure 
with two antiparallel 5- and 6-stranded -sheets.[12] A DALI 
five closest structural homologs with remarkable sequence 
homology (Z-score > 20, r.m.s.d. < 2.5 Å) despite sequence 
homologies of less than < 28 %. Two homologs are glutamine 
phosphoribosyl-pyrophosphate amidotransferase (PDB: 
1ECB and 1AO0; EC 2.4.2.14), one is a glutamine-fructose-6-
phosphate transaminase (PDB: 3OOJ; EC 2.6.1.16) and two 
are hypothetical proteins (PDB: 3MDN and 1TE5). The 
characteristic N-terminal nucleophile in EgtC is provided by 
the 1,2-aminothiol function of the N-terminal cysteine.[12] To 
liberate their N-terminal Ser-, Thr- or Cys-nucleophile, Ntn-
amidohydrolases usually undergo autocatalytic proteolysis. 
The observed electron density is consistent with an N-
terminal cysteine in EgtC. Because the egtC gene encodes 
this residue directly after Met1, we believe that activation of 
recombinant EgtC is afforded by endogenous methionine 
aminopeptidase activity in E. coli.[18] 
 
The apo form and the complexes with glutamine/glutamate or 
with sulfoxide 3 adopt very similar conformations (r.m.s.d. = 
0.176 Å) (Figure S1). The most mobile element is a loop 
consisting of residues Ala90 – Pro95 (Figures 2 and 3). In two 
structures (apo form and the glutamine/glutamate complex) 
this loop closes over the glutamyl binding site and positions 
Thr91 for hydrogen bonding with the ligand. Yet, in the 
sulfoxide 3 complex this loop adopts a more open 
conformation that stabilizes an unproductive substrate-
binding mode (see below). 
 
Figure 2. Left: Dimer of EgtCC2A in complex with sulfoxide 3. The substrate binding site maps to the dimer interface. Right: EgtC in complex with 
glutamine/glutamate (salmon, with m|Fo|-D|Fc| electron density; -level = 2.5). The mobile loop consisting of residues Ala90 – Pro95 is shown in red. 







Figure 3. Left: EgtCC2A in complex with sulfoxide 3 (salmon, with m|Fo|-D|Fc| electron density; -level = 2.5). Comparison with EgtC in complex with 
glutamine/glutamate (gray) shows an open conformation of the loop between Ala90 and Pro95. Right: Recognition of the betaine-moiety of sulfoxide 3. Met40 
and Asp43 from chain A (green) combine with Trp66 and Tyr30 from chain B (yellow) to form a hydrophobic pocket with excess negative charge to recognize the 
trimethyl ammonium moiety of sulfoxide 3. Ser89 (resolved in two conformations) makes the only specific contact to the imidazole ring of the substrate. 
EgtC co-crystallized with glutamine. We crystallized EgtCwt 
in the presence of 2.5 mM glutamine as a simple substrate 
analog. The resulting crystals contained a ligand in the EgtC 
active site  that may be glutamine or glutamate. The -amino 
acid moiety of the ligand is recognized by the side chains of 
Arg88 (2.7 Å  and 3.1 Å), Asp133 (2.7 Å), and the backbone 
Gly115 (3.2 Å)  (Figure 2). In this structure the Ala90 – Pro95 
loop adopts the closed conformation allowing Thr91 to form 
an additional hydrogen bond to the α-amino group of the 
ligand (2.9 Å). The side chain of the ligand reaches into the 
catalytic site represented by the catalytic nucleophile Cys2 
and an oxy-anion hole formed by the side chain of Asn114 
and the backbone at residue Gly115 which both coordinate 
the carbonyl oxygen of the ligand (3.0 Å and 2.8 Å).[19] To 
form this oxy anion hole Gly115 adopts a conformation which 
would be difficult to attain by an L-amino acid (φ   148°/ψ  -
147°). Consistently, the Asn114-Gly115 motif is highly 
conserved among all members of the GATase6/GATase4 
enzyme family.[20] The side chain of Asn114 is further 
immobilized by a hydrogen bond to Arg3 (2.9 Å). This 
interaction is common among EgtC-like proteins but it is 
absent in sequences outside this group of enzymes. 
The side chain of the ligand also interacts with the N-terminal 
amino group (3.1 Å) and the side chain of Ser89 (2.9 Å). The 
observation that both heteroatoms on the ligand side chain 
interact with hydrogen bond donors in addition to the cationic 
N-terminus indicates that the ligand may not be glutamine, 
but rather its hydrolysis product glutamate.  
 
EgtC in complex with sulfoxide 3. In the co-crystal of 
EgtCC2A with sulfoxide 3 we found a different binding mode for 
the glutamyl moiety together with an “open” conformation of 
the Ala90 – Pro95 loop. The α-amino acid function of the 
glutamyl moiety is still anchored by the same two salt bridges 
to Arg88 (2.7 Å and 3.5 Å) and Asp133 (3.0 Å) (Figure 3), but 
the Cα-Cβ bond points away from the active site, placing the 
scissile amid bond almost 8 Å away from the oxy anion-hole 
and the catalytic nucleophile. Instead, this amide bond is 
immobilized by two hydrogen bonds from the backbone at 
Thr91 (3.3 Å) and Gly115 (3.2 Å) (Figure 3). In this position, 
the substrate is clearly save from enzyme catalyzed 
hydrolysis. However, cursory computer modeling indicates 
that sulfoxide 3 can easily adopt a hydrolysis-competent 
binding mode providing that the Ala90 - Pro95 loop assumes 
a closed conformation. The trimethylhistidine moiety of 
sulfoxide 3 binds to a pocket at the interface between two 
EgtC chains (Figures 2 and 3). Residues Met40 and Asp43 
from chain A and Tyr30 and Trp66 from chain B combine to a 
large hydrophobic pocket with excess negative charge 
providing a typical binding site for the quaternary ammonium 
cation (Figure 3).[21] The carboxylate of the TMH moiety is 
coordinated by the backbone amides of residues Leu39 (3.3 
Å) and Met40 (3.2 Å). Finally, Ser89 (2.8 Å) makes the only 
specific interaction to the imidazole ring on sulfoxide 3.  
 
Conservation of substrate-binding residues. The three 
EgtC structures in complex with either substrate or product 
identify six residues contacting the -glutamyl moiety (Arg88, 
Thr91, Asn114, Gly115, Asp133 and Ser134), five residues 
recognizing the TMH fragment (Tyr30, Met40, Asp43, Trp66 
and Ser89) and Arg164 as a ligand to the cysteinyl sulfoxide 
fragment. Most actinobacterial EgtC homologs provide the 
same pattern of ligand interactions, which is consistent with 
their involvement in ergothioneine biosynthesis.[8a, 11] More 






surprisingly, we found most of these active site residues also 
in EgtC homologs that must have different functions. To detail 
this observation we compared representative EgtC 
sequences from four classes of organisms: a) bacteria that 
encode EgtC in a egtB/C/D ergothioneine biosynthesis cluster 
(M. smegmatis and Nostoc. sp); b) bacteria that encode EgtC 
in a different locus than EgtB and EgtD (Ralstonia pickettii 
and  Thioalkalivibrio nitratireducens); c) bacteria that lack 
egtB/D homologs (Bacillus subtilis, Waddlia chondrophila and 
Silicibacter pomeroyi); and finally d) fungi which do (Laccaria. 
biocolor; N. crassa) or do not (Saccharomyces. cereviesae) 
contain egtB/D genes.  
 
A phylogenetic tree[22] based on these homologs reveales the 
family of EgtC-like enzymes as a homogeneous group which 
does not distinguish between EgtC homologs from organisms 
which do produce ergothioneine (blue and green, Figure 4) 
and homologs from organisms which do not (gray, Figure 4). 
At the same time the family of EgtC-like enzymes is well 
separated from its closest neighbors, which is a group of 
uncharacterized glutamine amidohydrolase termed YafJ-like 
enzymes.[23] One apparent distinction between these two 
enzyme classes is the identity of residue 3, following the N-
terminal nucleophile Cys2. Whereas EgtC-like enzymes 
contain arginine as third residue (Arg3), YafJ-like proteins 
contain glutamate or glutamine at this position.  
 
In an alignment[24] of the same set of EgtC sequences we find 
the N-terminal nucleophile motif  (Cys2-Arg3) and all 
glutamyl-binding residues conserved (Arg88, Thr91, Asn114, 
Gly115, Asp133 and Ser134) (Figure 5). Less conserved are 
active site residues which recognize TMH (Tyr30 and Ser89) 
and the cysteinyl moiety (Arg164). Ser89, the only residue 
which contacts the imidazole ring of the substrate, occurs 
exclusively in close relatives of mycobacterial EgtC (T. 
nitratireducens, Nostoc. sp and B. subtilis, Figure 4 and 
Figure 5). More distant sequences contain a conserved 





Figure 4. Phylogenetic tree based on EgtC-like protein sequences (EgtC 
gene names or locus tags in brackets). gray: Species which do not contain 
egtB or egtD genes (Bacillus subtilis: BEST7613_5058; Saccharomyces 
cerevisiae: NP_014208.1; Waddlia chondrophila: YP_003709474.1; 
Silicibacter pomeroyi: Spo2029, PDB: 3MDN);  white: species which 
contain egtB/C/D genes which are not organized in a cluster (Ralstonia 
pickettii 12J: Rpic_4440; Thioalkalivibrio nitratireducens: YP_007216429.1; 
Neurospora crassa: CAD70842.1; Laccaria bicolor: XP_001873785.1); 
black: species which contain egtB/C/D genes assembled in one cluster (M. 
smegmatis: MSMEG_6248; Nostoc sp. PCC 7524: Nos7524_2665).[22] 
 
 
Figure 5. Alignment of EgtC sequence from M. smegmatis (light gray, residues 1 – 180) with homologs from bacterial and eukaryotic organisms (see Figure 4).[22, 
24] Conserved residues which make specific contacts to the sulfoxide substrate are highlighted (gray, Ser/Thr and Tyr/Phe are treated as equal). 







Origin of EgtC. A recent phylogenetic study identified many 
bacterial species which encode the ergothioneine 
biosynthesis proteins EgtD and EgtB but lack recognizable 
EgtC-homologs.[11] Conversely, our structure-based surveil 
identified EgtC-like enzyme in organisms which do not 
contain EgtD/B homologs, or do not involve EgtC in 
ergothioneine production (Figure 1).[10a, 10b] Both perspectives 
agree that the phylogenetic distribution of EgtC and EgtD/B 
are poorly correlated. Therefor, we think that the last common 
ancestor of EgtC-like enzymes evolved for a different purpose 
than ergothioneine production. In addition, from the active site 
conservation across EgtC-like enzymes we can infer that this 
ancestral function involved a substrate with significant 
similarities to  sulfoxide 3. This similarity made the ancestral 
EgtC-like enzyme an easy recruit for the assembly of the five-
step ergothioneine biosynthesis in actinobacteria. One 
adaption in the active site seems to have been the change of 
Ala to Ser at position 89. As discussed above, Ser89 may 
contribute to specific binding of sulfoxide 3 through a 
hydrogen bond to its TMH moiety (Figure 3).  
 
Avoiding the cysteine problem. The reason why 
actinobacteria chose GC as sulfur donor rather than 
cysteine, is not quite clear (Figure 1). One possible motivation 
for this adaption may have been the "cysteine problem":[25] 
The 1,2-aminothiol function of cysteine efficiently binds to 
redox active transition metals. These complexes catalyze 
production of reactive oxygen species.[25] Cells which grow 
under high partial O2 pressures may need to limit the 
concentration of intracellular cysteine. γGC provides a much 
safer cysteine equivalent because its -amino function is -
glutamylated. In addition, because γGC biosynthesis is ATP-
driven, this building block could accumulate  despite a very 
low steady state cysteine concentration. Hence, an ancestral 
actinobacterium may have  adopted EgtC and EgtA by 
horizontal gene transfer to optimize ergothioneine 
biosynthesis under O2 rich and/or cysteine poor conditions.  
 
Sulfoxide stereochemistry. Finally, we would like to 
highlight the stereochemistry of sulfoxide 3. The resolution of 
the EgtCC2A complex is below 1.8 Å which unambiguously 
establishes an S-configuration at the sulfur atom of the ligand 
(Figure S2). We can not make much of this information in 
terms of EgtC catalysis, because we do not yet know whether 
the sulfoxide function is in any way involved in EgtC catalysis. 
However, the stereochemistry of sulfoxide 3 illuminates an 
interesting aspect of the catalytic mechanism of EgtB, the 
sulfoxide synthase that makes this intermediate (Figure 1). 
We have recently described the structure of EgtB from 
Mycobacterium thermoresistibile in complex with GC, TMH 
and manganese (II).[8c] Based on this structure we proposed a 
catalytic mechanism as depicted in Figure 6. This mechanism 
predicts that the sulfoxide product  
 
Figure 6. Proposed reaction mechanism of EgtB. Binding of TMH, GC 
and O2 as ligands to the iron center forms the first reaction intermediate 
consisting of an iron (III)-superoxo species (a). This species is protonated 
to generate an iron (III)-hydroperoxo species and a GC based thiyl radical 
(b). This thiyl radical attacks TMH to form the thioimidazole function  (c and 
d). Finally, sulfoxidation of the thioether function completes the catalytic 
cycle as the enzyme is released in the reduced iron (II) state. The relative 
position of the TMH ligand and the O2-binding site observed in the crystal 
structure[8c] predict that sulfoxide 3 must have an S-configuration at the 
sulfur center. 
should have the same S-configuration at the sulfur atom as 
we have now confirmed by crystallography.  
Conclusions 
In this report we described the crystal structure of the 
ergothioneine biosynthetic amidohydrolase EgtC from M. 
smegmatis. EgtC removes the -glutamyl moiety from 
sulfoxide 3. Even though this activity may be specific to 
actinobacterial ergothioneine biosynthesis, EgtC-like 
enzymes occur in a broad range of bacterial and fungal 
organisms, where they presumably serve other functions. 
Conservation of most active site residues across all EgtC-like 
enzymes suggests that these homologs transform substrates 
with significant similarity to sulfoxide 3. This similarity may 
have facilitated the recruitment of EgtC to GC-dependent 
ergothioneine biosynthesis by actinobacteria. 
Experimental Section 
Protein production. The open reading frame of egtC (locus 
name: MSMEG_6248; UniProtKB entry: A0R5M9) was 
amplified from Mycobacterium smegmatis strain ATCC 
700084 / mc(2)155 genomic DNA.[8a] The resulting PCR 
product was digested with PciI and XhoI while the vector 
pET28a(+) (Novagen) was cut with NcoI and XhoI prior to 
ligation with the insert. The resulting plasmid 
pET28a(+)_EgtC_His6 was sequenced and encodes a protein 













where underlined letters indicate mutations with respect to 
the EgtC sequence deposited in the UniProtKB database and 
italic letters indicate the linker and the affinity tag. This 
construct was used to produce native and seleno-L-
methionine labeled EgtC for SAD phasing of the apo structure.  
The pET28a(+)_EgtC_His6 construct was regenerated to 
remove several mutations using the previous cloning strategy. 







was used for structure determination of the EgtCwt_Gln 
complex.  
An inactive variant EgtCC2A was generated by PCR 
amplification using primers EgtC_NcoI_s (5‘-ACT GTC CCA 
TGG CCC GGC ATG TGG CGT-3‘) and EgtC_Xho_as (5`-
ACT ATC CTC GAG CAG GGG TGT CAC GAC GAC-3‘) 
from plasmid pET28a(+)_EgtC_His6_new. The PCR product 
as well as pET28a(+) were digested with NcoI and XhoI prior 
to ligation of both components. The protein encoded on 







E. coli BL21(DE3) cells were employed in recombinant 
production of EgtCwt and EgtCC2A in LB (lysogeny broth) 
medium supplemented with 50 µg ml-1 kanamycin. For 
production of seleno-L-methionine labeled protein, E. coli 
BL21-Codon-Plus(DE3)-RIL cells were grown in artificial 
LeMaster medium suppressing L-methionine biosynthesis.[26] 
Expression was induced with 0.5 mM IPTG at an OD600 of 0.8. 
After vigorous shaking for 16 h at 25 °C, cells were harvested 
by centrifugation, resuspended in buffer A (50 mM phosphate 
pH 7.5, 300 mM NaCl, 5 mM β-mercaptoethanol) and lysed 
by sonication or in a microfluidizer. The lysate was clarified by 
centrifugation at 48000g for 1 h at 4 °C. All EgtC variants 
were purified on immobilized Ni2+ using 1 ml NTA Agarose 
(Qiagen) or a HiTrap IMAC sepharose FF column (GE 
Healthcare). After elution with buffer B (buffer A containing 
500 mM imidazole), the protein was loaded onto a HiLoad 
16/60 Superdex™75 prepgrade size exclusion 
chromatography column (GE Healthcare) primed with 20 mM 
Tris/HCl pH 7.5, 150 mM NaCl, 5 mM β-mercaptoethanol and 
connected to an ÄKTAprime FPLC system (GE Healthcare). 
Fractions containing pure protein were pooled and 
concentrated to 25 mg ml-1. The identity of the proteins and 
the incorporation of seleno-L-methionine were verified using 
ESI mass spectrometry. Purified proteins were flash frozen in 
liquid nitrogen and stored at -80 °C if not used immediately. 
No differences in crystallization behavior were observed 
between fresh and frozen protein. 
Sulfoxide production. Sulfoxide 3 was produced in an 50 ml 
reaction containing 1.5 μM EgtB from Mycobacterium 
thermoresistibile,[8c] 12 mM GC, 10 mM TMH, 2 mM 
ascorbate, 2 mM TCEP, 10 μM FeSO4 and 20 mM potassium 
phosphate buffer at pH 7.5. After incubation for > 12 h at 
room temperature the filtered solution was acidified to pH 6.0 
by addition of ammonium acetate. This solution was 
incubated with 4 ml Dowex resin for two hours. The resin was 
washed with 8 ml nano-pure water. The flow-through and 
washing fractions were combined, and incubated with 3 ml 
Dowex resin at pH 3. After washing with 12 ml nano-pure 
water, sulfoxide 3 was eluted with 250 mM ammonium 
hydroxide. 
Crystallization. Crystallization conditions for the EgtC 
variants were determined by the sitting drop vapor diffusion 
method using The JCSG Core Suites I-IV (and The PACT 
and The PEGS for EgtCwt) and then optimized using a 
hanging drop setup. Optimized crystals of native EgtCwt and 
seleno-L-methionine labeled EgtCwt  were obtained using 1 µl 
of 15 mg ml-1  EgtC mixed with 1 µl reservoir equilibrated 
against 500 µl reservoir (0.1 M MES pH 6.4, 10-12% (w/v) 
PEG 20.000) at 20 °C. Rod-shaped crystals grew after 2-4 
days. They were cryoprotected in 0.1 M MES pH 6.4, 10-12% 
(w/v) PEG 20.000, 35% (w/v) PEG 3350 and flash cooled in 
liquid nitrogen. Co-crystallization of EgtCwt (protein produced 
from pET28a(+)_EgtC_His6_new) with L-glutamine was 
achieved by mixing of 1 µl EgtC (20 mg ml-1) pre-incubated 
with 2.5 mM L-glutamine with 1 µl mother liquor equilibrated 
against 500 µl of reservoir (0.1 M sodium acetate pH 4.7, 
50%(v/v) ethylene glycol). Since no further cryoprotection 
was required, the crystals were directly flash cooled in liquid 
nitrogen for data collection.  
Initial crystal hits of EgtCC2A with sulfoxide 3 (termed 4NK in 
PDB entry 4ZFL) were optimized by mixing 1 µL of 16 mg ml-1  
EgtCC2A pre-incubated with 10 mM sulfoxide 3 and 1 µL of 
reservoir equilibrated against 500 µL of reservoir (0.1 M 
sodium citrate pH 5.2-5.4, 20% (w/v) PEG 6000) at 20 °C. 
Crystals were cryoprotected in reservoir solution 
supplemented with 20% (v/v) glycerol and 10 mM sulfoxide 3 
before plunging them in liquid nitrogen. 
Data collection, data processing, structure solution and 
refinement.  






Diffraction data sets of a native as well as a seleno-L-
methionine labeled EgtCwt crystal were collected on beamline 
PXII of the SLS (Swiss Light Source, Paul Scherrer Institute, 
Villingen, Switzerland) at cryogenic temperatures. Native 
EgtCwt data were collected at a wavelength of λ = 0.9792 Å, 
while single anomalous diffraction (SAD) data were collected 
at the Se K edge (λ= 0.9786 Å). According to Xtriage, 
anomalous differences were significant to 4.6 Å resolution.[27] 
Diffraction data of an EgtCwt_Gln complex were collected on 
beamline BL14.1 of BESSY II Synchrotron (Helmholtz Centre 
Berlin, Berlin, Germany) at a wavelength of λ=0.9184 Å, while 
diffraction data of an EgtCC2A_4NK crystals were collected on 
beamline P11 at PETRA III (DESY, EMBL Hamburg, 
Germany). Data indexing employed XDS and data scaling 
was performed with AIMLESS from the CCP4 suite.[28] 
Initial phasing and model building were achieved with Autosol 
from the Phenix software package, combining single 
anomalous diffraction data of a Se-Met labeled crystal with a 
native data set of EgtCwt in the same crystal form. The 
second crystal form was phased by molecular replacement, 
using one EgtC monomer in MOLREP.[29] Structure 
determination of EgtCC2A_4NK was achieved using a 
monomer of the EgtCwt apo structure in PHASER from 
Phenix.[30] 
Ligand restraints were prepared with PRODRG[31] and 
eLBOW.[32] Model building was done in COOT, followed by 
refinement in phenix.refine.[30c, 33] The structures were 
validated with MolProbity and deposited as PDB entries 4ZFJ 
(EgtCwt), 4ZFK (EgtCwt_Gln), and 4ZFL (EgtCC2A_4NK).[34] 
Details of data collection and refinement statistics are 
provided in Table S1 and S2. Figures were prepared with 
PyMOL.[35] 
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